Publicaciones en las que colabora con J. E. Megías (22)

2023

  1. Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

    Cancers, Vol. 15, Núm. 8

2022

  1. Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

    Cancers, Vol. 14, Núm. 8

  2. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients

    Annals of Hematology, Vol. 100, Núm. 6, pp. 1497-1508

  2. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

    Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938

  3. Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

    Leukemia and Lymphoma, Vol. 62, Núm. 11, pp. 2727-2736

  4. Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 612-620

  5. Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain

    European Journal of Haematology, Vol. 106, Núm. 5, pp. 724-733

  6. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 62, Núm. 3, pp. 659-668

  7. Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

    Pharmacogenetics and Genomics, Vol. 31, Núm. 6, pp. 133-139

2019

  1. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 3, pp. 197-218

  2. Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11

2018

  1. Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

    Pharmacogenomics Journal, Vol. 18, Núm. 2, pp. 301-307

  2. Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia

    Current Drug Metabolism, Vol. 19, Núm. 1, pp. 55-74

  3. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

    Annals of Hematology, Vol. 97, Núm. 7, pp. 1115-1153

2017

  1. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1197-1206

  2. Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

    Pharmacogenetics and Genomics, Vol. 27, Núm. 7, pp. 270-274

  3. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2880-2894

2016

  1. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia

    Pharmacogenomics Journal, Vol. 16, Núm. 1, pp. 30-40

  2. Pharmacogenomics and the treatment of acute myeloid leukemia

    Pharmacogenomics, Vol. 17, Núm. 11, pp. 1245-1272